Glenmark Pharma’s subsidiary has secured marketing authorisation in Germany for generic version of GlaxoSmithKline’s Seretide Accuhaler, which is used to treat asthma.
“Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name ‘Salflutin’,” the company said in a BSE filing.
Glenmark Pharmaceuticals Executive Vice President and Business Head of Europe and Latin America, Achin Gupta, said that upon launch, generic Fluticasone/Salmeterol DPI will be Glenmark’s first inhalation product available in Germany.
“There is a huge potential for the product in Germany and we are optimistic that it will help enhance growth of the European business,” he added.
Glenmark had entered into a development and licensing agreement with Celon Pharma S.A. to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product – Fluticasone/Salmeterol dry powder inhaler in 15 European countries.
The company has already launched this product in Denmark, Sweden and Norway. Quoting IQVIA data, Glenmark Pharma said Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of $844 million in Europe in the 12-month period ended March 2018. Shares of Glenmark Pharma were trading up by 2.17 per cent at Rs 698.05 on the BSE.
